Introduction Evidenced self-management to guide patients in preserving their quality of life (QoL) and moderate healthcare demands, is lacking in bronchiectasis though advocated in the guidelines.
Introduction There is a need for objective clinical endpoints in bronchiectasis to evaluate response to new and existing therapies. Current clinical endpoints in use present their own challenges; 24 hour sputum volume is unreliable, microbial clearance is often only assessed qualitatively and there remains controversy over changes in microbial load. Quality of life questionnaires (St George's Respiratory Questionnaire (SGRQ), Leicester Cough Questionnaire, Bronchiectasis Health Questionnaire and Quality of Life-bronchiectasis are subjective outcome measures. The mean exacerbations and time to first exacerbation have been used in phase 3 trials but there remains debate regarding the definition of an exacerbation. The incremental shuttle walk test (ISWT) is a measure of functional exercise capacity and more objective than the 6 min walk test; an endpoint associated with survival in COPD. Aim To evaluate the ISWT as an objective clinical endpoint in bronchiectasis by assessing its reliability, validity and responsiveness. Methods To assess reliability 30 patients were invited 6 months apart whilst clinically well to perform the ISWT. To assess validity the ISWT scores were correlated with total SGRQ and activity scores in 94 patients (stable and exacerbation). To assess responsiveness 30 patients performed the ISWT pre-and post 14 days of intravenous antibiotic therapy for an exacerbation, 94 patients performed pre and post 14 days of oral antibiotics for exacerbation and sub-analysis from a previous study evaluated ISWT in 30 patients pre and post 12 months of nebulised gentamicin therapy. Results There was no significant difference in median (IQR) distance walked at baseline (390 m (225 m -462.5 m)) and after 6 months (400 m (260 m -480 m)). There was a negative correlation between ISWT and total SGRQ (r=À0.60) and the activity component (r=À0.64) p<0.0001. There was a median increase of 18.5% in distance walked with nebulised gentamicin, 16.3% with oral antibiotic therapy and 11.9% with intravenous antibiotic therapy. 81% of patients had a more than 10% increase in distance walked with nebulised gentamicin, 61% with oral therapy and 50% with intravenous therapy (figure 1 Background Non-tuberculous mycobacterial (NTM) infection is more prevalent in those with bronchiectasis than the general population. In addition, Pseudomonas is frequently isolated in more severe bronchiectatic disease. We interrogated our non-CF bronchiectasis database to identify association. Method A retrospective analysis of 232 patients with non-CF bronchiectasis distinguished those both with and without NTM infection. Analysis included demographic, clinical, microbiologic, lung function and radiological data over a 10 year period. Results NTM were cultured in 29 patients (12.5%), M gordonae being the most frequent (n=11, 37.9%) followed by M avium-intracellulare (n=9, 31.0%). Pseudomonas infection, current or previous, was identified in 146 (62.9%). Of those with NTM infection, a history of Pseudomonas infection was very strongly associated (96.6%) with only a single case of NTM isolated without Pseudomonas (3.4%; p=0.001) (figure 1). Also, concurrent proton pump inhibitor use in the NTM group showed a strong association (55.2% vs. 29.06%; p=0.03). Conclusion A 10 year analysis of our non-CF bronchiectasis cohort indicates a very strong association between prior Pseudomonas infection and subsequent NTM isolation, with an NTM negative predictive value 98.8% in the absence of Pseudomonas. Whilst association is not causation, we postulate that Pseudomonas may lead to specific mucosal microbiome and structural changes. Moreover, this may be a necessary antecedent prior to observing the very high NTM prevalence rates found in this condition. Introduction Hypertonic saline (HTS) is commonly nebulised used to aid airway clearance in patients with chronic suppurative lung disease. In view of the risk of bronchoconstriction, prior to starting HTS, patients undergo a drug reaction assessment (DRA), as suggested by guidelines. 1 Patients that experience a>15% reduction in FEV1 post inhalation,+/-lack of tolerability, are deemed to have failed the DRA and would not usually be prescribed it for continued usage. We aimed to identify patient characteristics predicting a successful DRA and the likelihood of continuing HTS at 1 year post DRA. Methods A retrospective analysis of all HTS DRAs between April 2011 and March 2016 at the Royal Brompton Hospital was undertaken. Spirometry, age, gender and underlying disease were recorded and the variables associated with DRA success and continued use at 1 year were assessed with logistic regression.
Results 523 patients underwent an HTS DRA with overall 89.5% passing the test. There were 504 tests with 7% HTS (90.2% passed) and 18 tests with 3.5% HTS (73.7% passed). A higher FEV1% Predicted Pre-Trial (PPT) was significantly associated with passing the DRA with an Odds Ratio (OR) of 0.97 (95%CI: 0.95-0.98, p-value<0.001); patients with an FEV% PPT >61% had a 0.05% chance of failing the DRA. Patients diagnosed with ABPA or COPD were significantly more likely to fail the DRA for HTS with ORs of 3.07 (95% CI:1.15-8.1, p-value=0.025) and 3.38 (95%CI:1.06-10.76, pvalue-0.039), respectively. Amongst the 468 patients who passed the DRA, those with a higher FEV1% PPT were also more likely to remain on the HTS after 12 months, whilst, non-CF Bronchiectasis (OR: 0.44, p-value=0.020) and patients with "Other" lung diseases, including carcinoma and sarcoidosis, (OR:0.33, p-value=0.008) patients were significantly less likely to remain on it. Conclusions The vast majority of patients passed the HTS DRA test and the failure rate in those with FEV1 PPT >61% was extremely low. We propose that clinical phenotypes could be used to risk assess patients who need HTS DRA tests before starting HTS.
